Literature DB >> 16283884

Two Swedish founder MSH6 mutations, one nonsense and one missense, conferring high cumulative risk of Lynch syndrome.

K Cederquist1, M Emanuelsson, F Wiklund, I Golovleva, R Palmqvist, H Grönberg.   

Abstract

Lynch syndrome, or hereditary non-polyposis colorectal cancer (HNPCC), is a cancer susceptibility syndrome caused by germline mutations in mismatch-repair genes, predominantly MLH1, MSH2 and MSH6. A majority of the mutations reported are truncating, but for MSH6, missense mutations constitute over one third. Few have been proven pathogenic in functional studies or shown to segregate in families. In this study, we show segregation of the putative pathogenic MSH6 missense mutation c.1346T>C p.Leu449Pro with microsatellite instability-high Lynch syndrome-related tumours lacking MSH6 expression in a large 17th century pedigree. Another large family with the MSH6 nonsense c.2931C>G, p.Tyr977X mutation is similar in tumour spectra, age of onset and cumulative risk. These MSH6 families, despite their late age of onset, have a high lifetime risk of all Lynch syndrome-related cancers, significantly higher in women (89% by age 80) than in men (69%). The gender differences are in part explained by high endometrial (70%) and ovarian (33%) cancer risks added upon the high colorectal cancer risk (60%). The several occurrences of breast cancer are not due to the MSH6 mutations. These findings are of great importance for counselling, management and surveillance of families with MSH6 mutations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16283884     DOI: 10.1111/j.1399-0004.2005.00537.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  18 in total

1.  Association between MSH6 G39E polymorphism and cancer susceptibility: a meta-analysis of 7,046 cases and 34,554 controls.

Authors:  Zuming Li; Lihua Kong; Ling Yu; Jiao Huang; Ke Wang; Shi Chen; Miao Yu; Sheng Wei
Journal:  Tumour Biol       Date:  2014-03-13

2.  Lynch syndrome-associated breast cancers: clinicopathologic characteristics of a case series from the colon cancer family registry.

Authors:  Michael D Walsh; Daniel D Buchanan; Margaret C Cummings; Sally-Ann Pearson; Sven T Arnold; Mark Clendenning; Rhiannon Walters; Diane M McKeone; Amanda B Spurdle; John L Hopper; Mark A Jenkins; Kerry D Phillips; Graeme K Suthers; Jill George; Jack Goldblatt; Amanda Muir; Kathy Tucker; Elise Pelzer; Michael R Gattas; Sonja Woodall; Susan Parry; Finlay A Macrae; Robert W Haile; John A Baron; John D Potter; Loic Le Marchand; Bharati Bapat; Stephen N Thibodeau; Noralane M Lindor; Michael A McGuckin; Joanne P Young
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531

Review 3.  Cancer genetics: risks and mechanisms of cancer in women with inherited susceptibility to epithelial ovarian cancer.

Authors:  Lee P Shulman; Jeffrey S Dungan
Journal:  Cancer Treat Res       Date:  2010

4.  Risks of Lynch syndrome cancers for MSH6 mutation carriers.

Authors:  Laura Baglietto; Noralane M Lindor; James G Dowty; Darren M White; Anja Wagner; Encarna B Gomez Garcia; Annette H J T Vriends; Nicola R Cartwright; Rebecca A Barnetson; Susan M Farrington; Albert Tenesa; Heather Hampel; Daniel Buchanan; Sven Arnold; Joanne Young; Michael D Walsh; Jeremy Jass; Finlay Macrae; Yoland Antill; Ingrid M Winship; Graham G Giles; Jack Goldblatt; Susan Parry; Graeme Suthers; Barbara Leggett; Malinda Butz; Melyssa Aronson; Jenny N Poynter; John A Baron; Loic Le Marchand; Robert Haile; Steve Gallinger; John L Hopper; John Potter; Albert de la Chapelle; Hans F Vasen; Malcolm G Dunlop; Stephen N Thibodeau; Mark A Jenkins
Journal:  J Natl Cancer Inst       Date:  2009-12-22       Impact factor: 13.506

5.  Features of ovarian cancer in Lynch syndrome (Review).

Authors:  Kanako Nakamura; Kouji Banno; Megumi Yanokura; Miho Iida; Masataka Adachi; Kenta Masuda; Arisa Ueki; Yusuke Kobayashi; Hiroyuki Nomura; Akira Hirasawa; Eiichiro Tominaga; Daisuke Aoki
Journal:  Mol Clin Oncol       Date:  2014-08-20

6.  High risk of colorectal and endometrial cancer in Ashkenazi families with the MSH2 A636P founder mutation.

Authors:  Bhramar Mukherjee; Gad Rennert; Jaeil Ahn; Sara Dishon; Flavio Lejbkowicz; Hedy S Rennert; Stacey Shiovitz; Victor Moreno; Stephen B Gruber
Journal:  Gastroenterology       Date:  2011-03-16       Impact factor: 22.682

7.  Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule.

Authors:  Adam N Rosenthal; Lindsay Fraser; Ranjit Manchanda; Philip Badman; Susan Philpott; Jessica Mozersky; Richard Hadwin; Fay H Cafferty; Elizabeth Benjamin; Naveena Singh; D Gareth Evans; Diana M Eccles; Steven J Skates; James Mackay; Usha Menon; Ian J Jacobs
Journal:  J Clin Oncol       Date:  2012-12-03       Impact factor: 44.544

Review 8.  Recently identified colon cancer predispositions: MYH and MSH6 mutations.

Authors:  Fay Kastrinos; Sapna Syngal
Journal:  Semin Oncol       Date:  2007-10       Impact factor: 4.929

Review 9.  A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer.

Authors:  Tuya Pal; Jenny Permuth-Wey; Thomas A Sellers
Journal:  Cancer       Date:  2008-08-15       Impact factor: 6.860

10.  Sampling strategies for tissue microarrays to evaluate biomarkers in ovarian cancer.

Authors:  Jenny Permuth-Wey; David Boulware; Nikola Valkov; Sandra Livingston; Santo Nicosia; Ji-Hyun Lee; Rebecca Sutphen; Joellen Schildkraut; Steven Narod; Alex Parker; Domenico Coppola; Thomas Sellers; Tuya Pal
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-01       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.